BioSpace News Archive

Tetra Bio-Pharma Inc., a bio-pharmaceutical company engaged in cannabinoid-derived drug discovery and development, announces granting of a new patent from the Australian Patent Office for patent application number 2016268872.

Transparency Market Research has published a new report on the global cell separation technology market for the forecast period of 2019–2027.

Bacteriophage, also simply known as phages, are bacterial viruses that infect and feed on bacteria to replicate themselves.

StemPrintER Outperforms Oncotype DX in analysis with 800+ samples from ER+/HER2- postmenopausal breast cancer patients

Moberg Pharma AB announced that the total number of common shares in the company has increased to 19,223,510.

IONIQ Sciences Inc., which is changing the cancer landscape with a modern multi-cancer screening technology using its non-invasive Electrical Impedance Analytics technology and a proprietary algorithm, announced it is changing its name from ProLung, Inc. to IONIQ Sciences, Inc.

Reaching the revenues of over US$ 6 Bn at the end of 2019, the global neuropathic pain management market is projected for a healthy CAGR during the forecast period (2019 – 2029).

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

Health risks of unattended wounds or undue exposure to infected tissues are becoming an alarming concern in the healthcare industry of North America. Ineffectiveness of conventional wound care products continues to impede the surgical improvement of patients being treated with infected diseases.

According to the latest market report published by Persistence Market Research titled ‘Polycystic Ovary Syndrome Drugs Market: Global Industry Analysis and Forecast, 2016–2024’, the global polycystic ovary syndrome drugs market is expected to register a CAGR of 4.6% during the forecast period 2016–2024 and is expected to expand 1.5x in terms of revenue by 2024.